Exhibit 10.3
Form 10-KSB, 2001
Viral Genetics, Inc.
File No. 000-26875


AGREEMENT  OF BENEFIT OF  SERVICES  FOR THE  REGISTRY  OF A MEDICINE  CELEBRATED
BETWEEN SOLUCIONES  AVANZADAS PARA LA SALUD, S.A. DE C.V.,  HEREINAFTER REFERRED
TO AS "SAVAS,"  REPRESENTED BY ENG. ROGELIO IGARTUA RUILOBA AND DR. ALBERTO OSIO
SANCHO AND BY LABORATORIOS  SENOSIAIN,  S.A. DE C.V.  HEREINAFTER REFERRED TO AS
"SENOSIAIN,"  REPRESENTED BY JUAN SENOSIAIN AGUILAR, ALSO EXECUTES THIS DOCUMENT
THE FIRM VIRAL GENETICS,  INC. HEREINAFTER REFERRED TO AS VIRAL,  REPRESENTED BY
MR. HAMPAR KARAGEOZIAN, IN COMPLIANCE WITH THE FOLLOWING:


                                  DECLARATIONS

I.    Eng. Rogelio Igartua Ruiloba declares that:

     a). The company that he is representing is properly  constituted  according
to the Mexican Republic laws, according to the public writing number 10265 dated
September 24, 1999, Public Notary 211 of the Federal District, Lic. Jose Eugenio
Castaneda Escobedo.

     b). He holds the sufficient faculties for the celebration of this document,
same that has not been revoked to him nor modified in some term,  of  conformity
to the writing described in incised a).

     c).    Constituent   is   dedicated   among   other   activities   to   the
commercialization  and sale of  products  for the  health  and  among  them is a
pharmaceutical   product   developed  by  the  company  Viral  Genetics,   Ltd.,
hereinafter  referred  to as "THE  PRODUCT,"  the same  exclusively  focuses  to
counter-resist  the  effects  of the virus  identified  like AIDS  (syndrome  of
immunodeficiency  acquired)  patented  like VT 1 and/or  TNP,  US PATENT  OFFICE
(United States of North America) No. 08/641936, of conformity to the Contract of
Exclusive  Distribution that as ANNEXED A of this contract it comprises integral
part of the same one.

     d). The constituent  agrees in celebrating this agreement with "SENOSIAIN,"
in the terms and conditions that are stipulate ahead,  with object that this one
carries out the  necessaries  proceedings  to register  "THE PRODUCT" in name of
"SENOSIAIN" before the Mexican Health Authorities.

II.   Expresses Mr. JUAN SENOSIAIN AGUILAR that:

                                      E-16
<PAGE>


     a). The  constituent  represented  is a moral person  properly  constituted
according to the Mexican laws of  conformity to the public  writing  number 1661
dated April 12, 1965,  Public Notary 131 of the Federal  District.  Lic.  Andres
Ruiz Isunza.

     b). He holds the sufficient faculties for the celebration of this document,
same that has not been revoked to him nor modified in some term,  of  conformity
to the writing 4862 dated June 09, 1986,  Federal District,  Lic. Juan Guillermo
Dominguez Menezes.

     c). His represented  counts with the necessary  infrastructure,  equipment,
personnel,  knowledge  and  experience to carry out the registry and protocol of
"THE PRODUCT," because of it agrees in celebrating the same one with "SAVSA."

III.  Mr. Hampar Karageozian declares that:

     a). His represented is a firm properly constituted according to the laws of
the State of California in the United  States of North  America,  holding to the
date of sufficient  legal faculties for the  celebration of this document,  same
that has not been revoked to him nor modified in some term.

     b). The  constituent has developed in exclusive form a product to fight the
effects  of the AIDS  (syndrome  of  acquired  immunodeficiency),  same  that is
patented to its name under the denomination of VT 1 and/or TNP, US PATENT OFFICE
(United States of North America) No.  08/641936,  because of that it constitutes
like only holder of the rights that  derive from "THE  PRODUCT,"  as well as the
patent before described.

     c).  The  constituent  signed a Contract  of  Exclusive  Distribution  with
"SAVSA," same that is described  like ANNEXED A, an up to the date is effective,
being in agreement in ratifying this instrument with "SAVSA" and "SENOSIAIN."

Agreeing  the  contracting  parts  with the  above  declared,  they  agree  upon
committing  itself  in  the  terms  of  this  contract  with  subjection  to the
following:

                                     CLAUSES

FIRST:  "SAVSA"  designates in this act to "SENOSIAIN," like the only authorized
person to carry out the  registry of "THE  PRODUCT"  before the  Secretariat  of
Health.

SECOND.  "SENOSIAIN"  agrees in the designation that "SAVSA" makes in his favour
in conformity to the preceding clause, and by consequence it is committed to:

     1. To make all and each one of the  proceedings  that are necessary for the
registry of "THE PRODUCT,"  before the  Secretariat of Health and once obtaining
it, it is  committed  to endorse in favor of  "SAVSA"  or anyone  designates  by
"SAVSA" the inherent rights to the mentioned  registry in the terms that the law
for such effects  establishes,  in a term not greater than fifteen days, counted
from the dated of obtaining  the  confirmation  and the data of the  cessionary.
Being for the part of "SAVSA" the  obligation  of  accomplishing  the  necessary

                                      E-17
<PAGE>

negotiations  and  within the  periods  more  convenient  for  "SAVSA"  that the
registry is relinquished in favor of this last.

     2.  Parallelly to the registry of "THE PRODUCT,"  before the Secretariat of
Health, it will initiate the necessary tests relative to the protocol.

THIRD. As counterpart by the services of registry and protocol of "THE PRODUCT,"
"SAVSA" is committed to cover to "SENOSIAIN" the equivalent to 5% (five percent)
of the  monthly  sales  within the  Mexican  Republic,  against  delivery of the
receipt or  corresponding  invoice that comply with the fiscal  requirements  in
accordance  to the  Article 29 and 29-A of C.F.F.,  in the  understood  that the
referred  commission  will be covered by "SAVSA" once the last one has collected
the amount of such.

     Also "SAVSA" and "VIRAL" are  committed to cover by its  exclusive  account
all and each one of the  expenses in relation to the  clinical  protocol of "THE
PRODUCT."

FOURTH.

     a).  "SENOSIAIN"  and "VIRAL"  recognize that "SAVSA" is the only holder of
the rights inherent to the distribution  and sale of "THE PRODUCT."  "SENOSIAIN"
and "SAVSA" recognize that "VIRAL" is the legitim and absolute proprietor of the
trademark  that protects "THE PRODUCT"  specifically  the VT 1 and/or TNP in any
form or  incorporation  of the same one and by  consequence is also the owner of
the inherent  commercial  prestige or that will be able to be  attributed to the
trademark.

     b). It is understood  and been suitable that "SAVSA" has not authorized nor
empowered to  "SENOSIAIN"  to use the trademark in any different  character from
which is anticipated the present in contract. "SAVSA" is compelled to not to use
no brands of SENOSIAIN.

     c). "SENOSIAIN"  recognizes the titularity of "SAVSA" on and in relation to
all the sanitary  registries  relative to "THE PRODUCT" that will be carried out
later.

FIFTH:  "SENOSIAIN" accepts and recognizes that all the information contained in
the present contract and the periodic  information that "SAVSA" sends to him, as
well as the  rest of the  documentation  that it  receives  from the last one in
written form,  oral,  visual and samples,  will be considered like  confidential
comprising valuable of "SAVASA's" secrets, thus it agrees and it is committed to
maintain  this  information  and/or  documentation  privily,  and it will not be
provided,  revealed neither used nor before nor during nor with posterity to the
completion of this document,  with some different  intention  anticipated in the
present contract.

SIXTH.  The present  contract could not be yielded nor be  transmitted  total or
partially by "SENOSIAIN,"  without the previous writing consent of "SAVSA." Also
this contract could be solely  modified by means of the consent of both parts in
writing, signed by its properly authorized representatives.

                                      E-18
<PAGE>

SEVENTH.  "SENOSIAIN" is committed to apply the registration of "THE PRODUCT" in
a term of  sixty  (60)  days  from the date  that  "SAVSA"  gives to him all the
information required for this registry.

     The breach of this term will cause  recession of the  contract,  reason for
the execution of this contract.

EIGHTH.  For the effects of the present  contract the parts  indicate like their
addresses the following ones:

"SAVSA"                                   "SENOSIAIN"
Calle Tecamachalco No. 15 PH 1            Calle  Andres  Bello  No.  45, Piso 10
Col. Reforma Social                       Col. Polanco
Mexico 11000, D.F.                        Mexico 11560, D.F.

"VIRAL"

     All the warnings that are required or allowed  under the present  contract,
will be given in writing and given  personally or they will be sent by certified
mail with requested receipt or specialized  mail.  (Except for when another form
is anticipated.)

NINTH.  For all the relative to the  interpretation  and the  fulfillment of the
present  contract,  the parts are  specifically  put under the  jurisdiction and
competition of the Courts of Mexico City, Federal District, resigning to the law
that  because  of its  present  or  future  addresses  will  be  able  to get to
correspond to them.

Understood  the parts of the agreement and legal value of the present  document,
they ratify and sign it by  quadruplicated  in Mexico City,  Federal District to
eleventh day of the month of July of year two thousands one, not existing in him
error, dolo nor no other vice of the consent, conserving each one of the parts a
unit.

"SAVSA"
SOLUCIONES AVANZADAS PARA LA SALUD, S.A. DE C.V.


/s/ ING. ROGELIO IGARTUA RUILOBA          /s/ DR. ALBERTO OSIO SANCHO
Legal Representative                      Legal Representative


"SENOSIAIN"                               "VIRAL"
LABORATORIOS SENOSIAN, S.A. DE C.V.       VIRAL GENETICS, INC.


/s/ Q. JUAN SENOSIAIN AGUILAR             /s/ DR. HAMPAR KARAGEOZIAN
Legal Representative                      Legal Representative

                                      E-19